tbuckley/cabot-search huggingface dataset:
Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT.
Authors: Seema Singhal, A. Evens, O. Frankfurt, L. Gordon, R. Meagher, M. Tallman, S. Williams, J. Winter, L. Kaminer, D. Grinblatt, J. Mehta
Journal: Blood (2005)
Effect of thalidomide on the TGFβ-1-mediated synthesis of testosterone from DHEA in prostate cancer.
Authors: Tristan Sissung, C. Tyler Kirkland, Kelie M Reece, Julia T Arnold, William Douglas Figg
Journal: Journal of Clinical Oncology (2012)

141 Background: TGFβ-1 induces conversion of DHEA to testosterone in prostate cancer stromal cells. We hypothesized that thalidomide would inhibit TGFβ-1-mediated formation of testosterone from DHEA. Methods: We grew LAPC4 or LNCaP prostate cancer epithelial cells and 6S primary prostate stromal cells in mono-/co-culture with DHEA (100nM) and/or TGFβ-1 (40 or 100pM). Testosterone and PSA concentration in media were ascertained using ELISA and corrected for cell count using CCK8 (%DHEA controls). Results: TGFβ-1 and DHEA induced a dose-dependent increase in the formation of testosterone over controls (∼5-6 fold; P&lt;0.0001). Thalidomide (100μM) inhibited the formation of testosterone in cocultured cells treated with DHEA and TGFβ-1 (40pM) by 35% (P=0.0008). The thalidomide analogues, CPS49 (10μM) and lenalidomide (10μM) also had activity; CPS49 inhibited testosterone synthesis by 54% (P=0.010) while lenalidomide reduced testosterone by 15% (P=0.011). However, only thalidomide and CPS49 decreased median PSA secretion (40% and 93% respectively; P≤0.031). Other angiogenesis inhibitors (i.e., suramin (10μM) and sorafenib (500pM)) had no effect on testosterone synthesis (P&gt;0.05). Therefore, anti-androgen activity was not a class effect of antiangiogenesis agents. Ketoconazole also did not have activity suggesting that TGFβ-1-induced testosterone synthesis from DHEA evades standard therapies designed to inhibit androgen synthesis enzymes (i.e. CYP3A4 and CYP17 inhibitors). We assessed the phosphorylation status of TGFβ-1 pathway constituents (i.e., SMAD2/3, p38, JNK, and ERK) in cocultured cells treated as above. Thalidomide inhibits the phosphorylation of ERK without affecting total ERK levels; however, neither MEK inhibition (via U0126) nor Raf inhibition (via sorafenib) resulted in anti-androgenic effects in these cells suggesting that the canonical RAF/MEK/ERK pathway is not responsible for the difference in testosterone secretion phenotype. Conclusions: These results indicate that thalidomide and its analogues have anti-androgen activity and may explain the success of thalidomide and its analogues in clinical treatment of hormone-dependent and castration-resistant prostate cancer.
Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.
Authors: Ian W Flinn, John C. Byrd, Richard R Furman, Jennifer R Brown, Don M Benson, Steven E Coutre, Brad S Kahl, B. Douglas Smith, Nina D. Wagner-Johnston, Stephen E Spurgeon, Neill A. Giese, Albert S Yu
Journal: Blood (2009)
IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS
Authors: Carlos Moreno, Arne Lundblad, Elvin A. Kabat
Journal: The Journal of Experimental Medicine (1971)

The immunochemical properties of purified A(1) and A(2) glycoproteins have been compared to ascertain whether their antigenic determinants differ. Quantitative precipitin and complement-fixation studies using several anti-A sera as well as purified gammaG anti-A antibodies clearly showed a specificity difference. This was also supported by absorption studies: A(2) substance specifically removed antibodies reacting with A(2) substance leaving anti-A(1) activity. A(1) substance was more effective than A(2) substance in dissolving an A(1) anti-A(1)-specific precipitate. Purified gammaM anti-A hemolyzed A(1) cells more readily than A(2) cells. Inhibition studies using mono- and difucosyl type 2 A-active oligosaccharides showed that type 2 difucosyl receptors are present in A(2) substance. The structural basis for the specificity difference between A(1) and A(2) would appear to be that A(2) substances lack type 1 A determinants; this would account for the observed higher H and Le(b) activity in A(2) substances.
MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis
Authors: Celia S. L. Mak, Mingo M. H. Yung, Lynn M. N. Hui, Leanne L. Leung, Rui Liang, Kangmei Chen, Stephanie S. Liu, Yiming Qin, Thomas H. Y. Leung, Kai-Fai Lee, Karen K. L. Chan, Hextan Y. S. Ngan, David W. Chan
Journal: Molecular Cancer (2017)

Cancer metastasis is determined by the formation of the metastatic niche and the ability of cancer cells to adapt to microenvironmental stresses. Anoikis resistance is a fundamental feature of metastatic cancer cell survival during metastatic cancer progression. However, the mechanisms underlying anoikis resistance in ovarian cancer are still unclear.Expressions of miRNA-141 and its downstream targets were evaluated by qPCR, Western blotting, Immunohistochemical (IHC) and in situ hybridization (ISH) assays. The luciferase assays were used to prove KLF12 as the downstream target of miR-141. The cDNA microarray and apoptotic protein arrays were used to identify the targets of miR-141 and KLF12. The competition of KLF12 and Sp1 on survivin promoter was examined by ChIP assay. IHC analysis on ovarian cancer tissue array was used to evaluate the expressions of KLF12 and miR-141 and to show the clinical relevance. The functional studies were performed by in vitro and in vivo tumorigenic assays.Enforced expression of miR-141 promotes, while knockdown of miR-141 expression inhibits, cell proliferation, anchorage-independent capacity, anoikis resistance, tumor growth and peritoneal metastases of ovarian cancer cells. Bioinformatics and functional analysis identified that Kruppel-related zinc finger protein AP-2rep (KLF12) is directly targeted by miR-141. Consistent with this finding, knockdown of KLF12 phenocopied the effects of miR-141 overexpression in ovarian cancer cells. In contrast, restoration of KLF12 in miR-141-expressing cells significantly attenuated anoikis resistance in ovarian cancer cells via interfering with Sp1-mediated survivin transcription, which inhibits the intrinsic apoptotic pathway and is crucial for ovarian cancer cell survival, anoikis resistance and peritoneal metastases. Immunohistochemical (IHC) and in situ hybridization (ISH) assays confirmed that miRNA-141 expression is inversely correlated with KLF12 expression and significantly associated with advanced ovarian cancers accompanied with distal metastases, underscoring the clinical relevance of our findings.Our data identify a novel signaling axis of miR-141/KLF12/Sp1/survivin in enhancing anoikis resistance and likely serves as a potential therapeutic target for metastatic ovarian cancer.
Carious Lesions: Nanoparticle‐Based Targeting and Detection of Microcavities (Adv. Healthcare Mater. 1/2017)
Authors: Nathan A. Jones, Sywe‐Ren Chang, William J. Troske, Brian H. Clarkson, Joerg Lahann
Journal: Advanced Healthcare Materials (2017)

In article 1600883, Nathan Jones, Brian Clarkson, Joerg Lahann, and co-workers present a novel diagnostic technique for dental caries that is under development at the University of Michigan. The targeted fluorescent nanoparticle technology is based on edible starch for early detection of active carious lesions using a standard dental curing lamp.
Mutational Analysis of Thrombopietin, c-MPL and Jak2 Genes in Essential Thrombothethymia Patients - Identification of Concurrent Mutations of c-MPL and Jak2.
Authors: Jianmin Ding, Hirokazu Komatsu, Shinsuke Iida, Asahi Ito, Hiroki Yano, Masaki Ri, Atsushi Inagaki, Shigeru Kusumoto, Takashi Ishida, Masakazu Nitta, Ryuzo Ueda
Journal: Blood (2007)
Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience
Authors: Stephen S. Chung, Jenna D Goldberg, Esperanza B. Papadopoulos, Ann A. Jakubowski, Sean Devlin, Farid Boulad, Miguel Perales, Nancy A. Kernan, Doris M Ponce, Trudy N Small, Guenther Koehne, Juliet N Barker, Richard J. O'Reilly, Sergio A Giralt, Marcel R.M. van den Brink, James W. Young, Hugo R Castro-Malaspina
Journal: Blood (2012)
Outcome of Patients with Secondary Leukemias Managed with Different Treatment Strategies at a Single Center.
Authors: Arwa A.N. Abdelhameed, Joseph M. Brandwein, Kathy Chun, Vikas Gupta, Suzanne Kamel-Reid, Jeffrey H. Lipton, Mark D. Minden, Aaron D. Schimmer, Andre C. Schuh, Hans A. Messner
Journal: Blood (2005)
Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.
Authors: Andrew J. Carroll, Nyla A. Heerema, Julie M. Gastier-Foster, Caroline Astbury, Robert Pyatt, Shalini C. Reshmi, Michael J. Borowitz, Meenakshi Devidas, Stephen Linda, Mignon L. Loh, Elizabeth A. Raetz, Brent Wood, Naomi J. Winick, Stephen P. Hunger, William L. Carroll
Journal: Blood (2009)
Alternatives in the Evaluation of Suspected Coronary Heart Disease
Authors: Marcio Sommer Bittencourt, Juliano Lara Fernandes
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases
Authors: Saad Usmani, Rachael Sexton, Antje Hoering, Christoph Heuck, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan M Petty, John Crowley, Bart Barlogie
Journal: Blood (2011)
Adults miscoded and misdiagnosed as having pneumonia: results from the British Thoracic Society pneumonia audit
Authors: Priya Daniel, Thomas Bewick, Sally Welham, Tricia M Mckeever, Wei Shen Lim
Journal: Thorax (2017)

A key objective of the British Thoracic Society national community-acquired pneumonia (CAP) audit was to determine the clinical characteristics and outcomes of hospitalised adults given a primary discharge code of pneumonia but who did not fulfil accepted diagnostic criteria for pneumonia. Adults miscoded as having pneumonia (n=1251) were older compared with adults with CAP (n=6660) (median 80 vs 78 years, p&lt;0.001) and had more comorbid disease, significantly fewer respiratory symptoms (fever, cough, dyspnoea, pleuritic pain), more constitutional symptoms (general deterioration, falls) and significantly lower 30-day inpatient mortality (14.3% vs 17.0%, adjusted OR 0.75, p=0.003).
Antiviral Agents for Influenza
Authors: James R. Johnson
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Family Perspectives on Hospice Care Experiences of Patients with Cancer
Authors: Pallavi Kumar, Alexi A. Wright, Laura A. Hatfield, Jennifer S. Temel, Nancy L. Keating
Journal: Journal of Clinical Oncology (2017)

Purpose To determine whether hospice use by patients with cancer is associated with their families’ perceptions of patients’ symptoms, goal attainment, and quality of end-of-life (EOL) care. Methods We interviewed 2,307 families of deceased patients with advanced lung or colorectal cancer who were enrolled in the Cancer Care Outcomes Research and Surveillance study (a multiregional, prospective, observational study) and died by 2011. We used propensity-score matching to compare family-reported outcomes for patients who did and did not receive hospice care, including the presence and relief of common symptoms (ie, pain, dyspnea), concordance with patients’ wishes for EOL care and place of death, and quality of EOL care. We also examined associations between hospice length of stay and these outcomes among hospice enrollees. Results In a propensity-score-matched sample of 1,970 individuals, families of patients enrolled in hospice reported more pain in their patient compared with those not enrolled in hospice. However, families of patients enrolled in hospice more often reported that patients received “just the right amount” of pain medicine (80% v 73%; adjusted difference, 7 percentage points; 95% confidence interval [CI], 1 to 12 percentage points) and help with dyspnea (78% v 70%; adjusted difference, 8 percentage points; 95% CI, 2 to 13 percentage points). Families of patients enrolled in hospice also more often reported that patients’ EOL wishes were followed (80% v 74%; adjusted difference, 6 percentage points; 95% CI, 2 to 11 percentage points) and “excellent” quality EOL care (57% v 42%; adjusted difference, 15 percentage points; 95% CI, 11 to 20). Families of patients who received &gt; 30 days of hospice care reported the highest quality EOL outcomes. Conclusion Hospice care is associated with better symptom relief, patient-goal attainment, and quality of EOL care. Encouraging earlier and increased hospice enrollment may improve EOL experiences for patients with cancer and their families.
A Low Wells Score in a Hospital Setting May No Longer Safely Rule out Deep Vein Thrombosis: Preliminary Results From a Single-Center Prospective University-Hospital Study Involving 227 Patients.
Authors: Ynse IGV Tichelaar, Karina Meijer, Jan ter Maaten, Matthijs Oudkerk, Hanneke C. Kluin-Nelemans, Willem M. Lijfering
Journal: Blood (2009)
In Vivo Effects of Cyclosporine A, Mycophenolate Mofetile and Rapamycin on Adoptively Transferred CD4+CD25+ Regulatory T Cells in Prevention of Experimental Acute Graft-Versus-Host Disease.
Authors: Robert Zeiser, Vu Nguyen, Andreas Beilhack, Jeanette Baker, Stephan Schulz, Christopher H. Contag, Robert S. Negrin
Journal: Blood (2005)
<i>SMO</i>mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas
Authors: Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides
Journal: Neuro-Oncology (2016)

Meningiomas are the most common primary intracranial tumors in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the hope for targeted therapies. It would be useful to know the precise frequency of these mutations in anatomical subgroups and clarify their prognostic value.We used the Sanger sequencing technique to characterize 79 samples of olfactory groove meningiomas for SMO (L412F and W535L) and AKT1E17K mutations. We reviewed clinical data to assess the prognostic value of these mutations in this anatomical subgroup.Out of the 79 patients with olfactory groove meningiomas, we identified targetable mutations in 34 patients (43%) (22 patients [28%] with SMO mutation-L412F almost exclusively-and 12 patients [15%] with AKT1 mutation). Meningiomas in the SMO-mutant group had an overall 36% recurrence rate, significantly higher than in the AKT1-mutant group (16%) and in the "SMO and AKT1 wildtype" group (11%) (χ2 test, P = .04). All late recurrences (after 5 y) occurred in the SMO-mutant group. Among grade I meningiomas, the SMO-mutant group was identified as having a significantly poorer prognosis. World Health Organization histological grade II (P = .006) and incomplete resection (P = .001) were independently associated with shorter recurrence-free survival.Molecular diagnosis of SMOL412F/W535L and AKT1E17K mutations improves prognostic evaluation in olfactory groove meningiomas and opens new therapeutic perspectives with SMO or AKT inhibitors for recurrent cases.
Defining a Murine Model To Study Bone Disease in Multiple Myeloma (MM).
Authors: Paola Neri, Pierfrancesco Tassone, Zhenxin Shen, Nipun Patel, Robert Fajardo, Mariateresa Fulciniti, Rao Prabhala, Masood Shammas, Simona Blotta, Teru Hideshima, Dharminder Chauhan, John Muller, Salvatore Venuta, Brian D. Snyder, Steven R. Goldring, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2006)
Prevalence and Reversibility of Cardiac Dysfunction in Systemic Lupus Erythematosus: Improved Ventricular and Valvular Function after Disease Remission Following Hematopoietic Stem Cell Transplantation.
Authors: Yvonne Loh, Yu Oyama, Laisvyde Statkute, Kathleen Quigley, Kimberly Yaung, Walter Barr, Jurate Bucha, Richard K. Burt
Journal: Blood (2006)
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology
Authors: Jean-Pierre Droz, Gilles Albrand, Silke Gillessen, Simon Hughes, Nicolas Mottet, Stéphane Oudard, Heather Payne, Martine Puts, Gilbert Zulian, Lodovico Balducci, Matti Aapro
Journal: European Urology (2017)
Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.
Authors: Antonio M. Jimenez, George Behrens, John Maciejewski, Norman Wool, Elizabeth Shima Rich, Reem Karmali, Parameswaran Venugopal, Stephanie A. Gregory, Henry C. Fung, Sunita Nathan
Journal: Blood (2010)
Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients
Authors: Bharathi Aravamudan, Caili Tong, Martha Q. Lacy, Suzanne R. Hayman, Francis Buadi, Morie A. Gertz, Shaji Kumar, Angela Dispenzieri
Journal: Blood (2008)
Should we be concerned about air quality as a contributor to poor outcomes in lung transplant recipients?
Authors: Joel D. Kaufman, Ganesh Raghu
Journal: European Respiratory Journal (2017)

Recurrent and chronic rejection and infection are the principal reasons for poor outcomes in lung transplant recipients who manifest chronic lung allograft dysfunction (CLAD). The aetiology of CLAD is poorly understood and the prognosis is poor [1]. Indeed, environmental factors, including those from work, indoor sources and ambient sources (outdoors) that affect air quality, can be reasonably anticipated to affect the highly susceptible transplanted lungs as much as or more than healthy or diseased native lungs. Hence, there is an interest in studying whether environmental factors influence both the development and progression of post-transplantation complications including CLAD. Two new papers show adverse effects of air pollution following lung transplantation. What can we conclude? <http://ow.ly/Od1k306XIoD>
Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity
Authors: Hye-Mi Ahn, Jihye Ryu, Jin Myeong Song, Yunhee Lee, Hye-Jin Kim, Dongjoon Ko, Inpyo Choi, Sang Jick Kim, Jung Weon Lee, Semi Kim
Journal: Theranostics (2017)

The transmembrane four L6 family member 5 (TM4SF5) protein is a novel molecular target for the prevention and treatment of hepatocellular carcinoma.TM4SF5 is highly expressed in liver, colon, esophageal, and pancreatic cancers and is implicated in tumor progression.Here, we screened monoclonal antibodies that specifically bound to the extracellular loop 2 (EC2) of TM4SF5 from a phage-displayed murine antibody (single-chain variable fragment; scFv) library.We constructed and characterized chimeric antibodies, Ab27 and Ab79, of scFv fused with Fc domain of human IgG1.The affinity (KD) of Ab27 and Ab79 for soluble EC2 was approximately 9.2 nM and 16.9 nM, respectively, as determined by surface plasmon resonance analysis.Ab27 and Ab79 efficiently bound to native TM4SF5 on the cell surface were internalized into the cancer cells, leading to a decrease in cell surface TM4SF5.Ab27 and Ab79 inhibited the proliferation and invasion of TM4SF5-positive liver and colon cancer cells and reduced FAK and c-Src phosphorylation.Ab27 and Ab79 also enhanced anoikis sensitivity and reduced survivin.Ab27 mediated antibody-dependent cell-mediated cytotoxicity in vitro.Ab27 and Ab79 efficiently inhibited tumor growth in a liver cancer xenograft model.These results strongly support the further development of Ab27 as a novel anti-cancer agent in the clinic.
Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA)
Authors: Eiju Negoro, Naoko Hosono, Wenyi Shen, Tetsuichi Yoshizato, Bhumika J. Patel, Cassandra Hirsh, Bartlomiej Przychodzen, Michael J. Clemente, Reda Z. Mahfouz, Aleksandra Wodnar-Filipowicz, Hideki Makishima, Seishi Ogawa, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2015)